Skip to search formSkip to main contentSkip to account menu

NSC-102816

Known as: NSC 102816, NSC102816 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Azacitidine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute…
Abstract 3584 Background: Increasing age and worsening performance status (PS) are associated with low complete remission (CR… 
1982
1982
Phase II study of 5‐azacytidine in sarcomas of bone
Eight PATIENTS WITH OSTEOGENIC SARCOMA and seven patients with Ewing's sarcoma, all with advanced metastatic disease refractory… 
1980
1980
Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
Thirteen patients were treated with a hydroxyurea -- 5-azacytidine combination in an attempt to show an increase in therapeutic… 
1978
1978
Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC-45388) and a nitrosourea were treated… 
1975
1975
Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
5-Azacytidine is more active when administered parenterally than orally in the treatment of L1210 leukemic mice. Oral… 
1975
1975
Combination therapy with 5-azacytidine (NSC-102816) and methyl-GAG (NSC-32946) in previously treated adults with acute nonlymphocytic leukemia.
1974
1974
Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271).
1973
1973
Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study).
1972
1972
Phase I study of 5-azacytidine (NSC-102816) .
Thirty patients with various solid tumors were treated with 5-azacytidine. Total doses ranged from 1.0 to 24.0 mg/kg and were… 
1972
1972
Kinetics of the reduction in viability of cultured L1210 leukemia cells exposed to 5-azacytidine (NSC-102816).
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)